調査レポートカテゴリー： visiongain, 世界, 医療/バイオ

Pharma ADMET Testing: World Industry and Market Prospects 2015-2025

ADMET検査（吸収/分布/代謝/排泄/毒性検査）の世界市場：インビトロADMET検査、インビボADMET検査、インシリコADMET検査

◆タイトル：Pharma ADMET Testing: World Industry and Market Prospects 2015-2025
◆商品コード：VGAIN5102611
◆調査・発行会社：visiongain
◆発行日：2015年10月
◆ページ数：156
◆レポート形式：PDF / 英語
◆納品方法：Eメール
◆調査対象地域：グローバル
◆産業分野：医療・製薬
◆販売価格オプション（消費税別）

Single User	GBP1,799 ⇒換算￥269,850	見積依頼/購入/質問フォーム
Five User	GBP2,999 ⇒換算￥449,850	見積依頼/購入/質問フォーム
Site License（全社内共有可）	GBP4,999 ⇒換算￥749,850	見積依頼/購入/質問フォーム

※Single UserとDept Licence(Five User)の場合、DRM（デジタル著作権管理）付PDFファイルです。認証されたPC上のみでの閲覧と、PDF閲覧期限は購入日より1年となります。Dept Licence(Five User)は印刷できますが、Single Userは印刷できません。Site Licence/Global Site Licenseの場合は、閲覧・印刷制限はありません。
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※商品の納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。（振込先：三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はvisiongainの日本における正規販売代理店です。

【レポートの概要】

当調査レポートでは、ADMET検査（吸収/分布/代謝/排泄/毒性検査）の世界市場について調査・分析し、以下の構成でお届けいたします。

・レポートの概要
・イントロダクション
・ADMET検査の世界市場
　（市場規模予測、市場の成長要因・阻害要因など）
・ADMET検査の世界市場：セグメント別市場分析
　（インビトロADMET検査、インビボADMET検査、インシリコADMET検査）
・ADMET検査の世界市場：地域別市場分析、市場規模予測
・産業動向
・専門家の見解
・主要企業分析
・結論

ADMET Products and Services – Your Guide to Trends and Revenue Potentials
The pharma ADMET testing market gains much interest from pharmaceutical companies as they look to implement more-predictive ADMET testing. That finding and many others appear in a new report by visiongain.

Absorption, distribution, metabolism, excretion and toxicology (ADMET) testing is an integral part of drug development. Visiongain estimates the ADMET testing market was valued at $5.80bn in 2014, with the majority of revenues being attributed to in vitro testing.

Our new report gives you 51 tables, 48 charts and three interviews. Discover the most lucrative areas in that industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market, submarket and national level. You will see financial results, interviews, trends, opportunities, and revenue predictions for those pharma R&D technologies. There is much opportunity in that fast moving market.

Forecasts from 2015-2025 and other analyses show you commercial prospects
Besides revenue forecasting to 2025, our new study provides you with recent results, growth rates, and market shares. Discover qualitative analyses (including SWOT analysis) and commercial developments. Commercial drivers and restraints for each submarket are also provided, as are revenue forecasts to 2025.
• In vitro ADMET testing
• In vivo ADMET applications
• In silico ADMET uses.

Our new study predicts the pharma ADMET testing market will expand throughout the forecast period, 2015 to 2025, driven by increased demand for that screening and advances in technology enhancing the reliability and predictive capabilities of those assays.

Leading companies and potential for market growth
Overall revenue for the pharma ADMET testing market will reach $10.51bn in 2019, our work forecasts. We predict strong revenue growth through to 2025, as drug developers select stronger product candidates for development, using ADMET technology.

Our work also analyses prominent companies in that market. See visiongain’s analysis of leading companies, including these:
• Agilent Technologies
• BIOVIA
• Cyprotex
• Bio-Rad Laboratories
• Quintiles
• CMIC
• Charles River Laboratories
• WuXi PharmaTech
• Promega Corporation
• Sigma-Aldrich.

A company profile gives you the following information where available:
• Recent historical revenues
• Discussion of a company’s activities, technologies and outlook
• Brief assessment of the company’s ADMET strategy.

With that information you will assess competitors’ capabilities, progress, and commercial prospects, helping you stay ahead and benefit your reputation for insight.

National markets for those drug development technologies
Our study shows you prospects for ADMET sales in developed and developing countries. You will see individual revenue forecasts to 2025 for 12 countries:
• United States
• Japan
• Germany, France, United Kingdom, Italy and Spain (EU5)
• Brazil, Russia, India and China (BRIC)
• South Korea.

With our analysis you will investigate regions with highest revenues, demand and potential sales. Explore progress, needs and opportunities, seeing how you can gain.

What forces affect the pharma ADMET testing industry?
Our new report discusses issues and events affecting the pharmaceutical ADMET testing
industry and market. You will find discussions, including qualitative analyses:
• Rising demand for early ADMET testing
• Developments in that drug screening technology.

You will see discussions of technological, commercial, and economic issues, with emphasis on the competitive landscape and business outlooks. Discover what the future holds.

How Pharma ADMET Testing: World Industry and Market Prospects 2015-2025 helps
In particular, our new investigation gives the following knowledge to benefit your work:
• Revenue forecasts to 2025 for the pharma ADMET testing market – discover that industry’s commercial prospects, finding what revenues and growth are possible
• Revenue forecasts to 2025 for three submarkets – explore sales potentials of in vitro, in vivo and in silico testing
• Revenue forecasts to 2025 for 12 leading national markets – US, EU5 (Germany, France, UK, Italy and Spain), Japan, Brazil, Russia, India, China and South Korea
• Assessment of leading companies – assess competitors, exploring their product and service portfolios, strategic developments and commercial outlooks
• Exclusive interviews with three companies – gain opinions from MultiCASE Inc., Optivia Biotechnology and Takara Bio Europe AB, seeing what participants say and do
• Discussion of what stimulates and restrains companies and the market – examine forces affecting those technologies and their providers
• Prospects for established firms and those seeking to enter the industry – discover what the future holds, helping you stay ahead in knowledge.

There you will find quantitative and qualitative analyses with independent predictions. That way you will receive information that only our report contains, staying informed on business intelligence.

【レポートの目次】

1. Report Overview
1.1 Overview of the World Market for ADMET Testing
1.2 Why You Should Read This Report
1.3 How This Report Delivers
1.4 Main Questions Answered by This Analysis
1.5 Who Is This Study For?
1.6 Methods of Research and Analysis
1.7 Frequently Asked Questions (FAQs)
1.8 Some Associated Reports
1.9 About Visiongain

2. An Introduction to ADMET Testing
2.1 What Is ADMET Testing?
2.1.1 Absorption
2.1.2 Distribution
2.1.3 Metabolism
2.1.3.1 MIST Guidelines
2.1.4 Excretion
2.1.5 Toxicology
2.2 The Role of ADMET Testing in Biosimilarity
2.3 Trial Design and Execution
2.3.1 Phases of Drug Development
2.3.1.1 Phase 0 Trials: Establishing Pharmacodynamic and Pharmacokinetic Properties
2.3.1.2 Phase I Trials: First-In-Human Studies
2.3.1.3 Phase II Trials: Proof-Of-Concept
2.3.1.4 Phase III Trials: Preparing for Approval Applications
2.3.1.5 Post-Marketing Studies
2.3.2 Reducing Attrition Rates in Drug Development through Predictive ADMET
2.3.3 Benefits of Outsourcing

3. ADMET Testing: World Market 2015-2025
3.1 Pharma R&D Expenditures by Phase, 2014
3.1.1 The Impact of the Economy on the ADMET Testing Market, 2008-2014
3.1.2 Big Pharma Companies Are the Leading Clients for CROs
3.2 The ADMET Testing Market 2015-2025
3.2.1 What Will Drive Growth in ADMET Testing 2015-2025?
3.2.2 The ADMET Testing Market: Overall Revenue Forecast 2015-2025

4. ADMET Testing: Revenue by Segment 2015-2025
4.1 Which Market Sector Will Account for the Most Revenue from 2015-2025?
4.2 Rising Demand for Predictive ADMET Testing throughout the Decade
4.3 In Vitro ADMET Testing Market
4.3.1 In Vitro ADMET Testing: Drivers and Restraints
4.4 In Vivo ADMET Testing Market
4.4.1 In Vivo ADMET Testing: Drivers and Restraints
4.5 In Silico ADMET Testing
4.5.1 In Silico ADMET Testing: Drivers and Restraints

5. ADMET Testing: Leading Developed Markets 2015-2025
5.1 Leading National Markets for ADMET Testing 2014
5.2 ADMET Testing: Leading National Market Forecasts 2015-2025
5.3 North America as a Destination for Drug Development
5.3.1 The US: The Largest National Market for ADMET Testing 2015-2025
5.3.1.1 Government Programs to Improve ADMET in the US
5.3.2 The US: ADMET Testing Revenue Forecast 2015-2025
5.4 The Outlook for ADMET Testing in the EU5 2015-2025
5.4.1 Rewriting the Rules for Clinical Trials in the EU: Clinical Trials Regulation
5.4.2 EU5: Overall Market and Leading National Market Forecasts 2015-2025
5.4.3 Germany: Market Forecast 2015-2025
5.4.4 The UK
5.4.4.1 Overcoming Challenges in UK Clinical Trials
5.4.4.2 UK ADMET Testing Market Forecast 2015-2025
5.4.5 France: Market Forecast 2015-2025
5.4.6 Italy: Market Forecast 2015-2025
5.4.7 Spain: Market Forecast 2015-2025
5.5 Japan Is Being Challenged by Neighbouring Emerging Markets
5.5.1 Growth for ADMET Testing in Japan 2015-2025

6. ADMET: Leading Emerging Markets 2015-2025
6.1 Leading Emerging Markets for ADMET Testing 2014
6.1.1 Benefits of Conducting ADMET Testing in Emerging Markets
6.1.2 Challenges of Conducting Non-Clinical Studies in Emerging Markets
6.2 Strong Growth Forecast for Emerging ADMET Testing Markets 2015-2025
6.3 ADMET in Asia Pacific: An Emerging Market Perspective
6.3.1 China Will be the Largest Emerging Market for ADMET Testing in 2025
6.3.1.1 CRO Investments and Partnerships in China
6.3.1.2 Chinese ADMET Testing Market Forecast 2015-2025
6.3.2 India as a Hub for Clinical Trials
6.3.2.1 Indian ADMET Testing Market Forecast 2015-2025
6.3.3 South Korea
6.3.3.1 Promoting Local Drug Development in South Korea
6.3.3.2 Growth in the South Korean ADMET Market 2015-2025
6.4 Russia
6.4.1 Changing Drug Development Demands 2010-2015
6.4.2 Russian ADMET Market Forecast 2015-2025
6.5 Brazil: The Largest Market for Drug Development in Latin America 2015-2025
6.5.1 Brazilian ADMET Testing Market Forecast 2015-2025

7. Leading Companies in the ADMET Testing Industry 2014
7.1 Agilent Technologies, Inc.
7.1.1 Agilent Technologies, Inc.: Historical Revenues 2011-2014
7.1.2 Agilent Technologies, Inc. Acquires Cartagenia
7.2 Dassault Systèmes: Acquires Accelrys and forms BIOVIA
7.2.1 Accelrys: Historical Revenues 2011-2013
7.3 Cyprotex
7.3.1 Cyprotex Acquires CeeTox
7.3.2 Cyprotex Historical Revenues, 2010-2014
7.4 Bio-Rad Laboratories, Inc.
7.4.1 Bio-Rad Laboratories, Inc.: Historical Revenues 2011-2014
7.5 Quintiles
7.5.1 Expanding in Developed and Emerging Markets
7.6 Increasing Asian Regional Reach
7.6.1 CMIC Recent and Future Performance Analysis: An Asian Specialist
7.7 Charles River Laboratories Is an Expert in Pre-Clinical Services
7.8 WuXi PharmaTech
7.8.1 WuXi Acquires XenoBiotic Laboratories
7.8.2 WuXi Enters the Clinical Trial Services Market
7.9 Promega Corporation
7.10 Merck KGaA’s Acquisition of Sigma Aldrich

8. ADMET Testing Market: Industry Trends 2015-2025
8.1 Strengths and Weaknesses of the ADMET Testing Market
8.2 Opportunities and Threats in the ADMET Testing Market
8.3 ADMET Testing Market: STEP Analysis 2015-2025
8.3.1 Social Factors Affecting ADMET 2015-2025
8.3.2 Drug Developers Must Deal with Ethical Concerns for Animal Testing
8.4 Improving Technology for More Efficient Testing: High-Throughput Evaluation and In Vivo-Like Models
8.5 Economic Considerations for ADMET Testing 2015-2025
8.5.1 Demand for Predictive ADMET Testing
8.6 Political and Regulatory Developments Affecting ADMET Testing 2015-2025
8.6.1 Cutting Red Tape and Other Regulatory Developments in Drug Discovery and Development
8.6.2 Strategic Partnering for Long Term Revenue Growth
8.6.2.1 Sharing Risk Between Pharma and CROs
8.6.3 A Note on CRO Selection
8.6.3.1 Small Pharmaceutical Companies and CROs
8.6.4 CRO Consolidation is Decreasing the Number of Mid-Sized Market Players

9. Research Interviews
9.1 Interview with Dr Roustem Saiakhov, President of MultiCASE, Inc.
9.1.1 Addressing the Challenges in ADMET Testing
9.1.2 Trends in the ADMET Testing Market
9.2 Interview with Yong Huang, PhD, President and CEO of Optivia Biotechnology
9.2.1 ADMET Services at Optivia Biotechnology
9.2.2 Optivia’s Partnership with Rhenovia Pharma: CNS Drug Development
9.2.3 Optivia’s Partnership with Hurel Corporation: In Vitro-to-In Vivo Correlation
9.2.4 Challenges and Trends in Drug Discovery
9.2.5 Growth of Optivia Biotechnology in the Future?
9.3 Interview with Kristina Runeberg, Site Head of Takara Bio Europe AB
9.3.1 Acquisition of Cellectis AB
9.3.2 Addressing the Challenges in ADMET Testing
9.3.3 Trends in the ADMET Testing Market

10. Conclusions from Our Study
10.1 The World ADMET Testing Market in 2014
10.1.1 A Market Dominated by the Developed Countries
10.2 Strong Growth for the Overall Market 2015-2025
10.3 Which CROs Can Take Best Advantage of Market Growth in the Next 10 Years?
10.3.1 How Can CROs Specialise to Remain Competitive?

List of Tables
Table 1.1 ADMET Testing Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2025
Table 1.2 Foreign Currency Exchange Rates: Average Exchange Rate to USD, 2013 and 2014
Table 2.1 Pharmacokinetics: Description of ADME
Table 2.2 Drug Delivery Routes
Table 2.3 Biosimilar Guidance Drafted Using Elements of EU Guidelines, 2008-2015
Table 2.4 Founding Members of the ICH
Table 3.1 Breakdown of R&D Expenditures by Phase, 2014
Table 3.2 CRO Services Revenue by Customer Type, 2014
Table 3.3 ADMET Testing Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2025
Table 4.1 ADMET Testing Submarket Revenue ($bn) and Market Shares (%), 2014, 2019, and 2025
Table 4.2 ADMET Testing Submarket Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2025
Table 4.3 In Vitro ADMET Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2025
Table 4.4 In Vivo ADMET Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2025
Table 4.5 In Silico ADMET Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2025
Table 5.1 World ADMET Testing Market by National Market: Revenue ($bn) and Market Share (%), 2014
Table 5.2 ADMET Testing Market Forecast by Country: Revenue ($bn), AGR (%) and CAGR (%), 2015-2025
Table 5.3 ADMET Testing: Market Shares by Country, 2014, 2019 and 2025
Table 5.4 US ADMET Testing Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2025
Table 5.5 EU5 ADMET Testing Market by Country, 2014
Table 5.6 EU5 ADMET Testing Market Forecast by Country: Revenue ($bn), AGR (%) and CAGR (%), 2015-2025
Table 5.7 German ADMET Testing Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2025
Table 5.8 UK ADMET Testing Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2025
Table 5.9 French ADMET Testing Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2025
Table 5.10 Italian ADMET Testing Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2025
Table 5.11 Spanish ADMET Testing Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2025
Table 5.12 Japanese ADMET Testing Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2025
Table 6.1 Leading Emerging Markets for ADMET Testing, 2014
Table 6.2 Population Statistics in BRIC Nations, May 2015
Table 6.3 English Proficiency in Emerging Markets, 2014
Table 6.4 ADMET Testing Market Forecast in Emerging Markets: Revenue ($bn), AGR (%) and CAGR (%), 2015-2025
Table 6.5 Chinese ADMET Testing Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2025
Table 6.6 Indian ADMET Testing Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2025
Table 6.7 South Korean ADMET Testing Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2025
Table 6.8 Russian ADMET Testing Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2025
Table 6.9 Brazilian ADMET Testing Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2025
Table 7.1 Selected Companies in the ADMET Testing Industry, 2015
Table 7.2 Selected Agilent Technologies MS Products, 2015
Table 7.3 Agilent Technologies: Revenue ($bn), AGR (%) and CAGR (%), 2011-2014
Table 7.4 Agilent Technologies: Revenue ($bn) and Revenue Share (%) by Sector, 2013 and 2014
Table 7.5 Accelrys: Revenue ($bn), AGR (%) and CAGR (%), 2011-2013
Table 7.6 Cyprotex ADME & PK Services, 2015
Table 7.7 Cyprotex In Vitro Toxicology Services, 2015
Table 7.8 Cyprotex In Silico Services, 2015
Table 7.9 Cyprotex: Revenue ($bn and £bn), AGR (%) and CAGR (%), 2011-2014
Table 7.10 Bio-Rad Laboratories: Revenue ($bn), AGR (%) and CAGR (%), 2011-2014
Table 7.11 Quintiles: Service Revenue ($bn), AGR (%) and CAGR (%), 2010-2014
Table 7.12 CMIC: CRO Service Revenue ($bn and ¥bn), AGR (%) and CAGR (%), 2011-2014
Table 7.13 Charles River Laboratories: Revenue ($bn) and Revenue Share (%) by Sector, 2013 and 2014
Table 7.14 WuXi PharmaTech: Revenue ($bn) and CAGR (%) by Sector, 2012-2014
Table 8.1 ADMET Testing Market: Strengths and Weaknesses, 2015
Table 8.2 ADMET Testing Market: Opportunities and Threats, 2015
Table 8.3 ADMET Testing Market: STEP Analysis, 2015
Table 10.1 ADMET Testing Market by Sector: Revenue ($bn), CAGR (%) and Market Share (%), 2014, 2019 & 2025

List of Figures
Figure 2.1 Drug Design Process
Figure 2.2 ADMET Parameters
Figure 3.1 Breakdown of Pharma Clinical Spending by Phase, 2014
Figure 3.2 CRO Services Revenue by Customer Type, 2014
Figure 3.3 ADMET Testing Market: Drivers and Restraints, 2015-2025
Figure 3.4 ADMET Testing Market Revenue ($bn) Forecast, 2015-2025
Figure 4.1 ADMET Testing Market Revenue ($bn) by Submarket, 2014, 2019 and 2025
Figure 4.2 ADMET Testing Submarket Shares (%), 2014
Figure 4.3 ADMET Testing Submarket Shares (%), 2019
Figure 4.4 ADMET Testing Submarket Shares (%), 2025
Figure 4.5 ADMET Testing Market Revenue ($bn) Forecast by Submarket, 2015-2025
Figure 4.6 In Vitro ADMET Revenue ($bn) Forecast, 2015-2025
Figure 4.7 In Vitro ADMET: Drivers and Restraints, 2015-2025
Figure 4.8 In Vivo Submarket Revenue ($bn) Forecast, 2015-2025
Figure 4.9 In Vivo ADMET: Drivers and Restraints, 2015-2025
Figure 4.10 In Silico Testing Submarket Revenue ($bn) Forecast, 2015-2025
Figure 4.11 In Silico Submarket: Drivers and Restraints, 2015-2025
Figure 5.1 World ADMET Testing Market by National Market: Market Share (%), 2014
Figure 5.2 World ADMET Testing Market by National Market: Market Share (%), 2019
Figure 5.3 World ADMET Testing Market by National Market: Market Share (%), 2025
Figure 5.4 US ADMET Testing Market Revenue ($bn) Forecast, 2015-2025
Figure 5.5 EU5 ADMET Testing Market Share (%) by Country, 2014
Figure 5.6 EU5 ADMET Testing Market Revenue ($bn) Forecast, 2015-2025
Figure 5.7 German ADMET Testing Market Revenue ($bn) Forecast, 2015-2025
Figure 5.8 UK ADMET Testing Market Revenue ($bn) Forecast, 2015-2025
Figure 5.9 French ADMET Testing Market Revenue ($bn) Forecast, 2015-2025
Figure 5.10 Italian ADMET Testing Market Revenue ($bn) Forecast, 2015-2025
Figure 5.11 Spanish ADMET Testing Market Revenue ($bn) Forecast, 2015-2025
Figure 5.12 Japanese ADMET Testing Market Revenue ($bn) Forecast, 2015-2025
Figure 6.1 Leading Emerging Markets for ADMET Testing by Market Share (%), 2014
Figure 6.2 Cost Savings Available for Clinical Trials in Emerging Markets, 2014
Figure 6.3 Relative Competence in English in Emerging Markets, 2012
Figure 6.4 ADMET Testing: Emerging Market Revenue ($bn) Forecasts, 2015-2025
Figure 6.5 Chinese ADMET Testing Market Revenue ($bn) Forecast, 2015-2025
Figure 6.6 Indian ADMET Testing Market Revenue ($bn) Forecast, 2015-2025
Figure 6.7 South Korean ADMET Testing Market Revenue ($bn) Forecast, 2015-2025
Figure 6.8 Russian ADMET Testing Market Revenue ($bn) Forecast, 2015-2025
Figure 6.9 Brazilian ADMET Testing Market Revenue ($bn) Forecast, 2015-2025
Figure 7.1 Agilent Technologies: Revenue ($bn) and AGR (%), 2011-2014
Figure 7.2 Agilent Technologies: Revenue Share (%) by Sector, 2014
Figure 7.3 Accelrys: Revenue ($bn) and AGR (%), 2011-2013
Figure 7.4 Cyprotex: Revenue ($bn) and AGR (%), 2011-2014
Figure 7.5 Bio-Rad Laboratories: Revenue ($bn) and AGR (%), 2011-2014
Figure 7.6 Quintiles: Service Revenue ($bn) and AGR (%), 2010-2014
Figure 7.7 CMIC: CRO Service Revenue ($bn) and AGR (%), 2011-2014
Figure 7.8 Charles River Laboratories Clinical Trials: Revenue ($bn) by Sector, 2013 and 2014
Figure 7.9 WuXi PharmaTech: Revenue ($bn) by Sector, 2012-2014
Figure 10.1 ADMET Testing Market Revenue ($bn) by Sector, 2014, 2019 & 2025

【レポートのキーワード】

ADMET検査、吸収、分布、代謝、排泄、毒性、インビトロADMET検査、インビボADMET検査、インシリコADMET検査、製薬、薬物、医薬品

★調査レポート[ADMET検査（吸収/分布/代謝/排泄/毒性検査）の世界市場：インビトロADMET検査、インビボADMET検査、インシリコADMET検査] ( Pharma ADMET Testing: World Industry and Market Prospects 2015-2025 / VGAIN5102611) 販売に関する免責事項

[ADMET検査（吸収/分布/代謝/排泄/毒性検査）の世界市場：インビトロADMET検査、インビボADMET検査、インシリコADMET検査] ( Pharma ADMET Testing: World Industry and Market Prospects 2015-2025 / VGAIN5102611) についてEメールでお問い合わせ

◆H&Iグローバルリサーチ株式会社のお客様（例）◆